Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 5, 2011, Pages 538-543

  Fukao, Miki ^a   Ishida, Kazuya ^a   Sakamoto, Takuya ^a   Taguchi, Masato ^a   Matsukura, Hiroyoshi ^b   Miyawaki, Toshio ^a   Hashimoto, Yukiya ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Saiseikai Toyama Hospital   (Japan)

Author keywords

ABCC4; ABCG2; Bioavailability; Mizoribine; SLC28A1

Indexed keywords

MIZORIBINE;

ADULT; BREAST CANCER RESISTANCE PROTEIN GENE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1 GENE; DRUG BIOAVAILABILITY; DRUG URINE LEVEL; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MULTIDRUG RESISTANCE PROTEIN 4 GENE; NORMAL HUMAN; NOTE; URINALYSIS;

EID: 80055076447     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-NT-040     Document Type: Note

References (23)

1. Yokota, S.: Mizoribine: mode of action and effects in clinical use. Pediatr. Int., 44: 196-198 (2002).
2. Shibasaki, T., Koyama, A., Hishida, A., Muso, E., Osawa, G., Yamabe, H., Shiiki, H., Makino, H., Sato, H., Ishikawa, I., Maeda, K., Tomita, K., Arakawa, M., Ishida, M., Sato, M., Nagase, M., Kashihara, N., Yorioka, N., Koike, T., Saito, T., Harada, T., Mitarai, T., Sugisaki, T., Nagasawa, T., Tomino, Y., Nojima, Y., Kobayashi, Y. and Sakai, O.: A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin. Exp. Nephrol., 8: 117-126 (2004).
3. Ihara, H., Shinkuma, D., Kubo, M., Miyamoto, I., Nojima, M., Koike, H., Yabumoto, H. and Ikoma, F.: Influence of bioavailability on blood level of mizoribine in kidney transplant recipients. Transplant. Proc., 28: 1321-1323 (1996).
4. Gray, J. H., Owen, R. P. and Giacomini, K. M.: The concentrative nucleoside transporter family, SLC 28. Pflugers Arch., 447: 728-734 (2004).
5. Podgorska, M., Kocbuch, K. and Pawelczyk, T.: Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim. Pol., 52: 749-758 (2005).
6. Govindarajan, R., Bakken, A. H., Hudkins, K. L., Lai, Y., Casado, F. J., Pastor-Anglada, M., Tse, C. M., Hayashi, J. and Unadkat, J. D.: In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am. J. Physiol. Regul. Integr. Comp. PhysioL, 293: R1809-R1822 (2007).
7. Naito, T., Tokashiki, S., Mino, Y., Otsuka, A., Ozono, S., Kagawa, Y. and Kawakami, J.: Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin. Pharmacol. Toxicol., 106: 310-316 (2010).
8. Takano, M., Yumoto, R. and Murakami, T.: Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther., 109: 137-161 (2006).
9. Wang, X., Nitanda, T., Shi, M., Okamoto, M., Furukawa, T., Sugimoto, Y., Akiyama, S. and Baba, M.: Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem. Pharmacol., 68: 1363-1370 (2004).
10. de Wolf, C., Jansen, R., Yamaguchi, H., de Haas, M., van de Wetering, K., Wijnholds, J., Beijnen, J. and Borst, P.: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol. Cancer Ther., 7: 3092-3102 (2008).
11. Ishikawa, T., Tamura, A., Saito, H., Wakabayashi, K. and Nakagawa, H.: Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften, 92: 451-463 (2005).
12. Yamasaki, Y., Kusuhara, H., Sakaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., Higuchi, S. and Sugiyama, Y.: Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin. Pharmacol. Ther., 84: 95-103 (2008).
13. Russel, F. G., Koenderink, J. B. and Masereeuw, R.: Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci., 29: 200-207 (2008).
14. Takaai, M., Sakata, J., Ishida, K., Taguchi, M. and Hashimoto, Y.: Mechanisms for transport of methotrexate across apical and basolateral membranes in human intestinal epithelial Caco-2 cells. Jpn. J. Pharm. Health Care Sci., 36: 63-71 (2010).
15. Borst, P., Evers, R., Kool, M. and Wijnholds, J.: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 92: 1295-1302 (2000).
16. Reid, G., Wielinga, P., Zelcer, N., De Haas, M., Van Deemter, L., Wijnholds, J., Balzarini, J. and Borst, P.: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol., 63: 1094-1103 (2003).
17. Ban, H., Andoh, A., Imaeda, H., Kobori, A., Bamba, S., Tsujikawa, T., Sasaki, M., Saito, Y. and Fujiyama, Y.: The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol., 45: 1014-1021 (2010).
18. Ishida, K., Takaai, M., Yotsutani, A., Taguchi, M. and Hashimoto, Y.: Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells. Biol. Pharm. Bull., 32: 741-745 (2009).
19. Honda, M., Itoh, H., Suzuki, T. and Hashimoto, Y.: Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Biol. Pharm. Bull., 29: 2460-2464 (2006).
20. Beal, S. L., Boeckmann, A. J. and Sheiner, L. B.: "NONMEM Users Guides: NONMEM Project Group", University of California, San Francisco (1992).
21. Ishida, K., Takaai, M., Yotsutani, A., Yokota, A., Sakamoto, T., Taguchi, M., Matsukura, H., Miyawaki, T. and Hashimoto, Y.: Mechanisms responsible for different rates of uptake of mizoribine and ribavirine by human epithelial LS180 cells. Jpn. J. Pharm. Health Care Sci., 36: 900-905 (2010).
22. Kruh, G. D., Guo, Y., Hopper-Borge, E., Belinsky, M. G. and Chen, Z. S.: ABCC10, ABCC11, and ABCC12. PflugersArch., 453: 675-684 (2007).
23. Tanaka, M., Okazaki, T., Suzuki, H., Abbruzzese, J. L. and Li, D.: Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer, 117: 74-751 (2011).